Using artificial intelligence to design safer nanoparticles for targeted drug delivery
Artificial intelligence-integrated mechanistic modeling for rational design of nanoparticles to improve organ targeting and safety
This study is working on making tiny particles that can deliver medicine right where it's needed in the body, using smart computer technology to help design them better, so patients can get safer and more effective treatments with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10855721 on NIH RePORTER |
What this research studies
This research focuses on improving the design of nanoparticles (NPs) to enhance their ability to deliver drugs directly to specific organs while minimizing side effects. By utilizing artificial intelligence, the researchers aim to create a model that predicts how these nanoparticles behave in the body based on their structure and other factors. This approach involves analyzing existing data and conducting experiments to validate the model's predictions, ultimately leading to safer and more effective treatments for patients. The goal is to streamline the development of new nanomaterials for clinical use.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals requiring targeted therapies for conditions that could benefit from nanoparticle-based drug delivery.
Not a fit: Patients who do not require targeted drug delivery or those with conditions that are not addressed by nanoparticle therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer drug delivery systems for patients, reducing side effects and improving treatment outcomes.
How similar studies have performed: Previous research has shown promise in using artificial intelligence for drug delivery systems, indicating potential for success in this novel approach.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Dogra, Prashant — Methodist Hospital Research Institute
- Study coordinator: Dogra, Prashant
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.